Although patients with lung adenocarcinoma diagnosed at a younger age showed a lower incidence and percentage of EGFR mutations than patients diagnosed at the common age of onset, young and older patients did not demonstrate significant differences in the prevalence of ALK translocations and mutations in EGFR, KRAS, or TP53 (ALK: P = 0.509, EGFR: P = 0.125, KRAS: P = 0.552, TP53: P = 0.888, Table 1). Here, EGFR is linked to lung adenocarcinoma.